+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 18Years - 65Years
All Genders
Healthy Volunteers
ID07783243

Immune Response Screening of Vaccine Candidate Antigens in Ethiopian Patients With Cutaneous and Visceral Leishmaniasis

Led by Institute of Tropical Medicine, Belgium · Updated on 2026-08-24

90

Participants Needed

2

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying the immune response in Ethiopian patients with cutaneous and visceral leishmaniasis to better identify human vaccine targets. This observational study evaluates six specific Leishmania antigens identified using a sensitive method called immunopeptidomics, comparing these to a standard soluble Leishmania antigen. The goal is to understand how T-cells respond before and after treatment and to support the development of a test for monitoring treatment. Participants include patients with suspected cutaneous or visceral leishmaniasis and healthy Ethiopian volunteers without prior infection. Blood and tissue samples such as lesions, bone marrow, or spleen will be stimulated outside the body to measure the release of interferon-gamma, indicating T-cell activation. Samples are collected at baseline and end of treatment for antigen screening, while the standard antigen is assessed at multiple timepoints. Additional analyses will explore T-cell characteristics and how responses vary across different genetic backgrounds. During the study, participants provide samples at specified times including before and after treatment. Researchers will analyze immune responses using various laboratory techniques such as flow cytometry and sequencing. The study will measure the presence and strength of T-cell responses, their functional profiles, and how these relate to treatment outcomes. Safety and consent are ensured, with healthy volunteers serving as controls to differentiate specific immune responses from general activation. The study runs from baseline to up to 28 days after treatment starts.

CONDITIONS

Brief Title

Ex Vivo Immunogenicity Screening of Vaccine Candidate Antigen Combinations in Ethiopian Patients With Leishmaniasis

Research Team

E

Eshetu Molla, PhD

T

Thao-Thy Pham, PhD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here